TAGCyx Bio’s mission is to develop efficacious and safe medicines through our proprietary technology platform generating artificial oligonucleotide DNA aptamers. We will focus on developing innovative therapeutics medicines and medical devices that leverage the unique characteristics of Xenoligo® aptamers, particularly aiming to develop safe therapies for women who cannot take medicines due to possible pregnancy. Our core competence is the world-class proprietary technology, the committed team members under trust, and partnerships with our alliance partners with respect.
Director COO
Gen Watanabe
CFO & Administration Division, Vice President
Koichiro Kasahara
Drug Discovery and Development Division, Vice President
Miyuki Hori
Non Executive Director
Mikio Kawahara
UTokyo Innovation Platform Co., Ltd.
Chief Investment Officer
Non Executive Director
Takayuki Okabuchi
Tsukishima Kachidoki Law Office
Lawyer
Auditor
Hajime Kurachi
Full-time Auditor
Auditor
Takahiro Kono
Kono Certified Public Accountant and Certified Public Tax Accountant Office
CPA and CPTA
Auditor
Yoshiyuki Yamakawa
HIBIKI Partners Co., Ltd.
(Chairperson)